Indication and Limitation of Use

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use: as first-line therapy in combination… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13)… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use: as first-line therapy in combination with FOLFOX, as monotherapy following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy.

Vectibix® is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.

×
×

You are now leaving Vectibix.com

Please know that the sponsors of this site are not responsible for content on the site you are about to enter.

Cancel
Continue

Meet Roy*:

A patient with liver-limited mCRC

What characteristics distinguish this patient with liver-limited mCRC?

  • Patient
  • Roy*
  • Gender
  • Male
  • Age
  • 64
  • Occupation
  • Middle-school teacher

*A hypothetical case study of a patient eligible for first-line mCRC therapy.

  • Medical history
  • Mild hyperlipidemia, controlled on statin therapy
  • Presentation
  • 3-month history of worsening constipation, bloating, and blood in stool
  • Colonoscopy confirmed 4-cm, non-obstructing mass in the left colon
  • Pathology report
  • Moderately differentiated adenocarcinoma
  • Performance status
  • ECOG PS = 1
  • Laboratory results
  • ALT: 70 U/L; AST: 180 U/L
  • CBC: Moderate anemia (9.2 g/dL)
  • Mutational status
  • KRAS wild type (not RAS mutant)
  • Imaging results
  • CT scan indicated liver-limited metastases: 2 bilobar lesions (right: 3.5 cm; left: 6.5 cm)
  • Surgery consult on metastatic disease
  • Potentially resectable metastases, but not upfront R0 resection
  • Surgeon feels metastatic disease is potentially resectable—treatment goal is to downgrade the tumor

ALT = alanine aminotransferase; AST = aspartate aminotransferase; CBC = complete blood count; CT = computed tomography; ECOG PS = Eastern Cooperative Oncology Group Performance Status; mCRC = metastatic colorectal cancer; R0 resection = complete resection.

Site Map
×